Acute graft dysfunction due to pyelonephritis, value and safety of graft biopsy

Objectives. To assess the value and safety of graft biopsy in patients who develop graft dysfunction due to pyelonephritis. Methods. Data analysis of all the patients with graft dysfunction and diagnosis of pyelonephritis was made on graft biopsy. During one year period six patients developed graft dysfunction due to pyelonephritis, all of these patients had an episose of acute cellular rejection in early post transplant period and received pulse steroid, while two in addition received ATG. Graft dysfunction when associated with UTI recovered within 4-6 weeks of antibiotic therapy. Graft biopsy is safe and histological diagnosis of pyelonephritis can save a patient from risk of anti rejection therapy given blindly in cases of graft dysfunction

Comparative evaluation of two once-a-month contraceptive injection

Two once-a-month preparations cyclo provera [Depo-medroxy Progesterone Acetate 25 mg and Estradiol Cypionate 5 mg] and HRP-102 [Norethisterone enanthate 50 mg and Estradiol Valerate 5 mg] were tried in two groups of women by random allocation, and their effectiveness, complaints and reasons for discontinuation were studied. A total of 206 women were admitted [104 on cyclo provera and 102 on HRP-102] and studied for one year. There was little difference in the efficacy and side-effects between the two preparations. One pregnancy occurred with HRP-102 giving a pregnancy rate of 1.4%. The overall discontinuation rates at 1 year were 57.6% for cycloprovera and 54.9% for HRP-102. The discontinuation rates for bleeding irregularities, were 21.2% and 21.81/o respectively for cycloprovera and HRP-102. Five women discontinued due to lack of bleeding or amenorrhoea. The respective figures were 4 and 1 for cyclo provera and HRP-102. Both products were highly effective and, if introduced in the national Family Planning Programme, they will fulfill an important role